0000000000685741

AUTHOR

Philip A. Kalra

0000-0001-7652-1572

showing 1 related works from this author

Newer formulations of intravenous iron: a review of their chemistry and key safety aspects - hypersensitivity, hypophosphatemia, and cardiovascular s…

2021

Introduction: The newest intravenous (IV) iron products show an improved safety profile over predecessors, allowing for the rapid administration of relatively high doses. Ferric derisomaltose (FDI; also known as iron isomaltoside), ferric carboxymaltose (FCM), and ferumoxytol (FER), are successful treatments for iron deficiency (Europe; FDI and FCM) and iron deficiency anemia (US; FDI, FCM, and FER).Areas covered: This review focusses on the chemistry and structure of FDI, FCM, and FER, and on three key aspects of IV iron safety: (1) hypersensitivity; (2) hypophosphatemia and sequelae; (3) cardiovascular safety.Expert opinion: Although the safety of modern IV iron has improved, immediate in…

medicine.medical_specialtySide effectAnemiaHypophosphatemia030204 cardiovascular system & hematologyDrug Hypersensitivity03 medical and health sciences0302 clinical medicinemedicineHumansPharmacology (medical)Intensive care medicineAnemia Iron-Deficiencybusiness.industryGeneral MedicineIron deficiencymedicine.diseaseFerumoxytolIron-deficiency anemiaCardiovascular Diseases030220 oncology & carcinogenesisFerricAdministration IntravenousbusinessAnaphylaxisHypophosphatemiaIron Compoundsmedicine.drugExpert opinion on drug safety
researchProduct